Compare · NXTS vs UAN
NXTS vs UAN
Side-by-side comparison of Nexentis Technologies Inc. (NXTS) and CVR Partners LP (UAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NXTS and UAN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- UAN is the larger of the two at $1.40B, about 1376.9x NXTS ($1.0M).
- Over the past year, NXTS is down 97.6% and UAN is up 46.5% - UAN leads by 144.0 points.
- NXTS has hit the wire 4 times in the past 4 weeks while UAN has been quiet.
PerformanceNXTS-97.55%UAN+46.49%
2025-10-20+0.00%2026-10-16
- Company
- Nexentis Technologies Inc.
- CVR Partners LP
- Price
- $0.61-2.56%
- $131.36-0.37%
- Market cap
- $1.0M
- $1.40B
- 1M return
- -48.05%
- -1.05%
- 1Y return
- -97.55%
- +46.49%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 0
UAN
CVR Partners LP
CVR Partners, LP, together with its subsidiaries, produces and distributes nitrogen fertilizer products in the United States. The company offers ammonia products for agricultural and industrial customers; and urea and ammonium nitrate products to agricultural customers, as well as retailers and distributors. CVR GP, LLC serves as the general partner of the company. CVR Partners, LP was founded in 2007 and is based in Sugar Land, Texas.
Latest NXTS
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
- Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
- SEC Form 8-K filed by Nexentis Technologies Inc.
- SEC Form PRE 14A filed by Nexentis Technologies Inc.
- Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
- Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
- Nexentis Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Nexentis Technologies Inc.
- Nexentis Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Latest UAN
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CVR Partners Reports Second Quarter 2026 Results
- CVR Partners to Release Second Quarter 2026 Earnings Results
- New insider Roberts Richard J. Jr. claimed ownership of 517 units of Common Units (SEC Form 3)
- CVR Partners 2025 Schedule K-3 Now Available
- CVR Energy and CVR Partners Announce Leadership Changes
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CVR Partners Reports First Quarter 2026 Results